title: Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations.
abstract: The discovery of JAK2 V617F mutation in the mid-2000s started to fill the gap between clinical presentation of polycythemia vera (PV), first described by Vaquez at the end of the 19th century, and spontaneous erythroid colony formation, reported by Prchal and Axelrad in the mid-1970s. The knowledge on this mutation brought an important insight to our understanding of PV pathogenesis and led to a revision of the World Health Organization diagnostic criteria in 2008. JAK-STAT is a major signaling pathway implicated in survival and proliferation of hematopoietic precursors. High prevalence of JAK2 V617F mutation among myeloproliferative neoplasms (>95% in PV and ~50% in primary myelofibrosis and essential thrombocythemia) together with its role in constitutively activating JAK-STAT made JAK2 a privileged therapeutic target. Ruxolitinib, a JAK 1 and 2 inhibitor, has already proven to be efficient in relieving symptoms in primary myelofibrosis and PV. In the latter, it also appears to improve microvascular involvement. However, evidence regarding its potential role in altering the natural course of PV and its use as an adjunct to current standard therapies is sparse. Therapeutic advances are needed in PV as phlebotomy, low-dose aspirin, cytoreductive agents, and interferon alpha are the only therapeutic tools available at the moment to influence outcome. Even though several questions are still unanswered, this review aims to serve as an overview article of the potential role of ruxolitinib in PV according to current literature and expert opinion. It should help hematologists to visualize the place of this tyrosine kinase inhibitor in the field of current practice and offer criteria for a careful patient selection.
authors.affiliation: Service and Central Laboratory of Hematology, CHUV, University Hospital of Lausanne, Lausanne, Switzerland.
authors.forename: Sabine
authors.initials: S
authors.lastname: Blum
authors.affiliation: Service and Central Laboratory of Hematology, CHUV, University Hospital of Lausanne, Lausanne, Switzerland.
authors.forename: Filipe
authors.initials: F
authors.lastname: Martins
authors.affiliation: Service and Central Laboratory of Hematology, CHUV, University Hospital of Lausanne, Lausanne, Switzerland.
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Alberio
keywords: JAK2 JAK1 inhibitor; JAK2 V617F; myeloproliferative neoplasms; polycythemia vera; ruxolitinib